Five sites for nine patients? Sounds expensive and reactive now.
"Although the inclusion criteria for this Phase I/II(a) trial are appropriately strict due to the non-withdrawable nature of TT-034, once a suitable safety profile has been established for the therapeutic, many of the trial exclusion parameters will be relaxed, enabling the treatment of much larger groups of patients."
I think this was the statement that had me thinking they might extend. I took safety profile to be good by cohort three and perhaps a few more people added to the later cohorts. Now I see he meant Phase 2B. These sites will probably stay on board for 2B.
- Forums
- ASX - By Stock
- BLT
- Sanofi Signs Benitec's closest competitor Voyager for $845M
Sanofi Signs Benitec's closest competitor Voyager for $845M, page-29
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online